JP2010530403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530403A5 JP2010530403A5 JP2010512761A JP2010512761A JP2010530403A5 JP 2010530403 A5 JP2010530403 A5 JP 2010530403A5 JP 2010512761 A JP2010512761 A JP 2010512761A JP 2010512761 A JP2010512761 A JP 2010512761A JP 2010530403 A5 JP2010530403 A5 JP 2010530403A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- carboaryl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 230000001225 therapeutic effect Effects 0.000 claims 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 13
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 13
- 125000001931 aliphatic group Chemical group 0.000 claims 13
- 125000005488 carboaryl group Chemical group 0.000 claims 13
- 208000010877 cognitive disease Diseases 0.000 claims 7
- 208000027061 mild cognitive impairment Diseases 0.000 claims 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 125000006413 ring segment Chemical group 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 230000006986 amnesia Effects 0.000 claims 2
- 125000000129 anionic group Chemical group 0.000 claims 2
- -1 diaminophenothiazine compound Chemical class 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000037149 energy metabolism Effects 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000006996 mental state Effects 0.000 claims 1
- 230000002438 mitochondrial effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94500607P | 2007-06-19 | 2007-06-19 | |
| US60/945,006 | 2007-06-19 | ||
| PCT/GB2008/002066 WO2008155533A2 (en) | 2007-06-19 | 2008-06-17 | Phenothiazine compounds for treating mild cognitive impairment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010530403A JP2010530403A (ja) | 2010-09-09 |
| JP2010530403A5 true JP2010530403A5 (enExample) | 2011-08-04 |
| JP5725605B2 JP5725605B2 (ja) | 2015-05-27 |
Family
ID=39943003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512761A Active JP5725605B2 (ja) | 2007-06-19 | 2008-06-17 | 軽度認知障害を処置するためのフェノチアジン化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9211294B2 (enExample) |
| EP (1) | EP2167095B1 (enExample) |
| JP (1) | JP5725605B2 (enExample) |
| CN (1) | CN101820884B (enExample) |
| AU (1) | AU2008265045B2 (enExample) |
| BR (1) | BRPI0813670A2 (enExample) |
| CA (1) | CA2690746C (enExample) |
| DK (1) | DK2167095T3 (enExample) |
| ES (1) | ES2739546T3 (enExample) |
| HR (1) | HRP20191513T1 (enExample) |
| HU (1) | HUE045460T2 (enExample) |
| MY (1) | MY177001A (enExample) |
| PL (1) | PL2167095T3 (enExample) |
| PT (1) | PT2167095T (enExample) |
| SI (1) | SI2167095T1 (enExample) |
| WO (1) | WO2008155533A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007008550D1 (de) | 2006-03-29 | 2010-09-30 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung |
| MY161656A (en) * | 2007-10-03 | 2017-04-28 | Wista Lab Ltd | Therapeutic use of diaminophenothiazines |
| US8785434B2 (en) | 2010-04-30 | 2014-07-22 | Prosetta Antiviral Inc. | Antiviral compounds |
| US8828986B2 (en) | 2011-04-20 | 2014-09-09 | Prosetta Antiviral Inc. | Antiviral compounds |
| RS55237B1 (sr) | 2011-02-11 | 2017-02-28 | Wis Ta Laboratories Ltd | Fenotiazin diaminijum soli i njihova primena |
| PL3686181T3 (pl) * | 2013-01-30 | 2024-11-04 | Ecolab Usa Inc. | Zmiatacze siarkowodoru |
| US10304006B2 (en) * | 2013-02-15 | 2019-05-28 | The Charles Stark Draper Laboratory, Inc. | Method for integrating and fusing heterogeneous data types to perform predictive analysis |
| CA2976776C (en) | 2015-02-17 | 2023-06-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
| KR102475825B1 (ko) * | 2016-07-25 | 2022-12-08 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| EP4364801B1 (en) * | 2018-07-26 | 2025-11-12 | TauRx Therapeutics Management Ltd. | Optimised dosage of diaminophenothiazines in populations |
| MY209608A (en) * | 2019-04-10 | 2025-07-24 | Genting Taurx Diagnostic Centre Sdn Bhd | Adaptive neurological testing method |
| GB201909454D0 (en) * | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Lab Ltd | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| KR20250154422A (ko) | 2023-03-03 | 2025-10-28 | 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 | 미세혈관 뇌질환 치료를 위한 디아미노페노티아진 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0017060D0 (en) * | 2000-07-11 | 2000-08-30 | Hunter Fleming Ltd | Production, stabilisation and use of reduced forms of pharmaceutical compounds |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| WO2004087160A1 (en) * | 2003-04-03 | 2004-10-14 | Prana Biotechnology Ltd | Treatment of neurological conditions |
| CN101084204B (zh) * | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
| EP2322517B1 (en) * | 2004-09-23 | 2019-04-24 | WisTa Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| WO2006091728A2 (en) * | 2005-02-24 | 2006-08-31 | The Trustees Of The University Of Pennsylvania | Microtubule stabilizing compounds and methods of their use |
| AU2007231126B2 (en) | 2006-03-29 | 2012-11-01 | TauRx Therapeutics Management Ltd | Inhibitors of protein aggregation |
| EP2853293B1 (en) | 2006-03-29 | 2017-11-22 | WisTa Laboratories Ltd. | Thioninium compounds and their use |
| DE602007008550D1 (de) * | 2006-03-29 | 2010-09-30 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazinsalze und ihre verwendung |
| US7956183B2 (en) | 2006-07-11 | 2011-06-07 | Wista Laboratories Ltd. | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
-
2008
- 2008-06-17 PL PL08762390T patent/PL2167095T3/pl unknown
- 2008-06-17 CN CN2008801031955A patent/CN101820884B/zh active Active
- 2008-06-17 MY MYPI20095255A patent/MY177001A/en unknown
- 2008-06-17 HR HRP20191513 patent/HRP20191513T1/hr unknown
- 2008-06-17 BR BRPI0813670-0A2A patent/BRPI0813670A2/pt not_active Application Discontinuation
- 2008-06-17 ES ES08762390T patent/ES2739546T3/es active Active
- 2008-06-17 CA CA2690746A patent/CA2690746C/en active Active
- 2008-06-17 AU AU2008265045A patent/AU2008265045B2/en active Active
- 2008-06-17 HU HUE08762390A patent/HUE045460T2/hu unknown
- 2008-06-17 WO PCT/GB2008/002066 patent/WO2008155533A2/en not_active Ceased
- 2008-06-17 US US12/665,608 patent/US9211294B2/en active Active
- 2008-06-17 DK DK08762390.6T patent/DK2167095T3/da active
- 2008-06-17 PT PT08762390T patent/PT2167095T/pt unknown
- 2008-06-17 EP EP08762390.6A patent/EP2167095B1/en active Active
- 2008-06-17 SI SI200832080T patent/SI2167095T1/sl unknown
- 2008-06-17 JP JP2010512761A patent/JP5725605B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530403A5 (enExample) | ||
| JP2009531404A5 (enExample) | ||
| JP7407740B2 (ja) | Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態 | |
| JP2019104748A5 (enExample) | ||
| JP2005533868A5 (enExample) | ||
| AU2012274160B2 (en) | Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo- N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide | |
| JP2012507522A5 (enExample) | ||
| ES2773543T3 (es) | Benzoimidazol-2-ilpirimidinas moduladores del receptor de histamina H4 | |
| TW200529850A (en) | Methods of preparing aripiprazole crystalline forms | |
| JP2009528271A5 (enExample) | ||
| JP2009526034A5 (enExample) | ||
| JP2011520832A5 (enExample) | ||
| JP2014511898A5 (enExample) | ||
| JP2010155827A5 (enExample) | ||
| JP2009506014A5 (enExample) | ||
| JP2010521516A5 (enExample) | ||
| ES2907590T3 (es) | Método para preparar un derivado heterocíclico | |
| JP2018529643A (ja) | ユビキチン化−プロテアソーム系に関連する化合物および薬学的組成物 | |
| JP2025131661A (ja) | ２－（５－（４－（２－モルホリノエトキシ）フェニル）ピリジン－２－イル）－ｎ－ベンジルアセトアミドの固体形態 | |
| JP2025538506A (ja) | がんの治療のための縮合ピリジンの固体形態 | |
| ES2820857T3 (es) | Síntesis y formas de sal novedosas de (R)-5-((E)-2-pirrolidin-3-ilvinil)pirimidina | |
| TW201018668A (en) | Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives | |
| JP6129471B2 (ja) | （＋）−１，４−ジヒドロ−７−［（３ｓ，４ｓ）−３−メトキシ−４−（メチルアミノ）−１−ピロリジニル］−４−オキソ−１−（２−チアゾリル）−１，８−ナフチリジン−３−カルボン酸の製造方法 | |
| JP2009525292A5 (enExample) | ||
| JP2006511498A5 (enExample) |